A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 25 Oct 2017
At a glance
- Drugs AAV2 GDNF (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- 14 Dec 2016 Planned End Date changed from 1 Jan 2018 to 1 Dec 2027.
- 14 Dec 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2025.
- 25 Aug 2016 According to a uniQure media release, top-line data from this trial are expected in the first quarter of 2017.